EFFECT OF ORAL ADMINISTRATION OF MICROENCAPSULATED LACTIC ACID BACTERIA IN A METABOLIC SYNDROME MURINE MODEL

M. RUSSO; A. SANTACRUZ; M.C. ABEIJÓN MUKDSI; R. MEDINA; P. GAUFFIN CANO; A. MARQUEZ; A. LÓPEZ-MALO

San Miguel de Tucumán

Simposio; V Simposio Internacional de Bacterias Lácticas; 2016

CERELA-CONICET

Metabolic syndrome (MS) is a term used in recent years for a group of risk factors including visceral obesity, hypertension, hyperglycemia and atherogenic dyslipidemia, which predispose the individual to develop cardiovascular disease and type 2 diabetes. Feruloyl esterases (FE) are enzymes that catalize the hydrolytic release of ferulic acid (FA), present in vegetable foods. FA is a phenolic acid with proven antioxidant, hypoglycemic and lipid lowering activities. Lactobacillus fermentum CRL1446 (Lf CRL1446) and Lactobacillus johnsonii CRL1231 (Lj CRL1231) are potential probiotic strains selected for their FE activity capable of releasing FA in vitro. The administration of lactic acid bacteria (LAB) with FE activity could improve metabolic markers present in animal models of MS. The aim of the present work was to evaluate the effect of oral administration of spray-dried microcapsules containing Lf CRL1446 or Lj CRL1231 on metabolic markers in a mice model of MS. Six week old male Swiss albino mice were divided into six groups (n = 6, each) and daily fed for a period of 7 weeks with a standard diet (control group) and a hyperlipidemic diet (MS group). Mice received by gavage three types of microcapsules: I) empty (non-treated group), II) containing Lf CRL1446 (Lf group) or III) containing Lj CRL1231 (Lj group). The administration dose was 107 CFU/day/mouse. Animals were sacrificed at week 7. Adiposity index was calculated. FE activity was determined in gut content using methyl ferulate as substrate. Released FA was detected by HPLC. Animal metabolic status was evaluated by determination of plasmatic glucose concentration and lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides). Results showed that body weight gain was higher after 7 weeks in mice from MS group, which presented an adiposity index significantly higher than that from control group, whereas no significant differences were observed among the three groups receiving microcapsules. Total intestinal FE activity showed ~1.2 fold increase in mice receiving microencapsulated LAB compared to non-treated group. Plasmatic levels of fasting glucose were higher in MS group compared to control group, and a significant decrease in Lf group was observed compared to non-treated mice. A significant reduction in the levels of total cholesterol, LDL-cholesterol and triglycerides in Lf and Lj groups was also observed. According to these results, oral administration of spray-dried microcapsules containing Lf CRL1446 and Lj CRL1231 increases intestinal FE activity and induces beneficial metabolic changes for prevention/treatment of MS.